IQUB inhibitors belong to a specialized category of chemical compounds designed to target and modulate the activity of IQUB, which stands for IQ Motif Containing Ubiquitin E3 Ligase Binding Protein. IQUB is a protein that interacts with ubiquitin E3 ligases, which are enzymes responsible for tagging proteins with ubiquitin molecules, marking them for degradation by the proteasome or lysosome. While the specific functions of IQUB are still an area of ongoing research, it is believed to play a role in the regulation of protein turnover and degradation. Inhibitors of IQUB are developed to interact with this specific protein, influencing its interactions with ubiquitin E3 ligases, its cellular localization, or its participation in cellular processes related to protein degradation and turnover.
Structurally, IQUB inhibitors are carefully designed to engage specific regions or binding sites on the IQUB protein. This interaction may disrupt the normal functioning of IQUB, affecting its ability to interact with ubiquitin E3 ligases, regulate protein ubiquitination, or participate in cellular processes that involve protein degradation. The mechanisms by which IQUB inhibitors exert their effects can vary, but their primary objective is to serve as valuable tools for researchers studying the roles of IQUB in various cellular contexts. Investigating the biochemical and functional aspects of IQUB and its modulation by inhibitors can contribute to a deeper understanding of protein turnover, quality control mechanisms, and the broader field of molecular and cellular biology. Ultimately, such research can offer insights into the intricate molecular mechanisms that govern fundamental cellular functions related to protein degradation and cellular homeostasis.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor that can prevent protein degradation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Targets the 26S proteasome complex in cells. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Irreversible proteasome inhibitor. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Selectively inhibits the chymotrypsin-like activity of the 20S proteasome. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
A more bioavailable form of Ixazomib, which targets the proteasome. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Naturally occurring selective proteasome inhibitor. | ||||||
PR 619 | 2645-32-1 | sc-476324 sc-476324A sc-476324B | 1 mg 5 mg 25 mg | $77.00 $188.00 $431.00 | 1 | |
Broad-spectrum DUB inhibitor. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
Inhibits ubiquitin-activating enzyme E1. | ||||||
P22077 | 1247819-59-5 | sc-478536 | 10 mg | $165.00 | ||
Inhibits deubiquitinating enzymes USP7 and USP47. | ||||||